EUVIMEDEUVIMED entdecken
Open Access

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis

Regina Castaneda iD, Dima Bechenati iD, Rene de J Rivera Gutierrez iD, Maria A Espinosa iD, Jose Villamarin iD, Elif Tama iD, Nancy Safwan iD, Sima Fansa iD, Alfredo Verastegui iD, Allyson W McNally iD, Jesse L Meek, Kristin C Cole iD und 6 weitere

Obesity · 2026-09 · 34 (S2) · 132-145

DOI: 10.1002/oby.70231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 14.06.2026. Verfasst von Regina Castaneda und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Tirzepatide, Weight Loss, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mayo Clinic Center for Women's Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real‐world clinical practice.

Methods

We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed ≥ 12 months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46–59, ≥ 60 years).

Results

Among 1039 patients (57% women; mean age 56 ± 11 years), women achieved significantly greater TBWL% than men after 15 months of treatment (15.1% vs. 10.7%, p < 0.001). Patients aged ≤ 45 years had greater weight loss than those ≥ 60 years (15.1% vs. 12.3%, p = 0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain‐promoting medications, and higher tirzepatide dosage. Age was not an independent predictor.

Conclusions

Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months. These findings underscore the importance of incorporating sex‐specific considerations into personalized obesity treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideWeight LossObesityAnti-Obesity AgentsOverweightHumansRetrospective StudiesFemaleMaleMiddle AgedSex FactorsAge FactorsTreatment OutcomeAgedAdult

Stichwörter der Autor:innen

ageobesitysex differencestirzepatideweight loss

Substanzen

TirzepatideAnti-Obesity Agents

Autor:innen und Institutionen

  • Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Endocrinology, Mayo Clinic, Jacksonville, Florida, USA.
  • Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Internal Medicine, Henry Ford Rochester Hospital, Detroit, Michigan, USA.
  • Division of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Regina Castaneda, Dima Bechenati, Rene de J Rivera Gutierrez, Maria A Espinosa, Jose Villamarin, Elif Tama, Nancy Safwan, Sima Fansa, Alfredo Verastegui, Allyson W McNally, Kristin C Cole, Stacey J Winham, Tamim I Rajjo, Andres Acosta, Stephanie S Faubion, Chrisandra L Shufelt, Maria D Hurtado Andrade

Förderung

  • Mayo Clinic Center for Women's Health Research

Zitieren

APA

Castaneda, R., Bechenati, D., Rivera Gutierrez, R. J., Espinosa, M. A., Villamarin, J., Tama, E., Safwan, N., Fansa, S., Verastegui, A., McNally, A. W., Meek, J. L., Cole, K. C., Winham, S. J., Rajjo, T. I., Acosta, A., Faubion, S. S., Shufelt, C. L., & Hurtado Andrade, M. D. (2026). Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis. Obesity, 34(S2), 132-145. https://doi.org/10.1002/oby.70231

Vancouver

Castaneda R, Bechenati D, Rivera Gutierrez RJ, Espinosa MA, Villamarin J, Tama E, et al. Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis. Obesity. 2026;34(S2):132-145. doi:10.1002/oby.70231

BibTeX
@article{Castaneda2026,
  author = {Castaneda, Regina and Bechenati, Dima and Rivera Gutierrez, Rene de J and Espinosa, Maria A and Villamarin, Jose and Tama, Elif and Safwan, Nancy and Fansa, Sima and Verastegui, Alfredo and McNally, Allyson W and Meek, Jesse L and Cole, Kristin C and Winham, Stacey J and Rajjo, Tamim I and Acosta, Andres and Faubion, Stephanie S and Shufelt, Chrisandra L and Hurtado Andrade, Maria D},
  title = {Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {S2},
  pages = {132--145},
  doi = {10.1002/oby.70231}
}
Kostenlos starten →